Co-delivery of VEGF and Bcl-2 dual-targeted siRNA polymer using a single nanoparticle for synergistic anti-cancer effects in vivo

Journal of Controlled Release

Volumn 220, Issue , 2015, Pages 631-641

  Lee, So Jin ^a   Yook, Simmyung ^a   Yhee, Ji Young ^b   Yoon, Hong Yeol ^a,c   Kim, Myung Goo ^a,c   Ku, Sook Hee ^a   Kim, Sun Hwa ^a   Park, Jae Hyung ^c   Jeong, Ji Hoon ^c   Kwon, Ick Chan ^a,d   Lee, Seulki ^e   Lee, Hyukjin ^b   Kim, Kwangmeyung ^a  

^a Korea Institute of Science and Technology   (South Korea)

^b Ewha Womans University   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Korea University   (South Korea)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Dual gene delivery; Glycol chitosan; Nanoparticle; siRNA polymer; Tumor targeted delivery

Indexed keywords

CHITIN; CHITOSAN; DISEASES; GENE TRANSFER; GENES; GENETIC ENGINEERING; GLYCOLS; NANOPARTICLES; ONCOLOGY; POLYMERS; RNA; TUMORS;

CHEMICALLY MODIFIED; GENE DELIVERY; GENETIC MUTATIONS; GLYCOL CHITOSAN; MULTIFACTORIAL DISEASE; SINGLE NANOPARTICLE; SYNERGISTIC EFFECT; TUMOR TARGETED DELIVERY;

GENE THERAPY;

ANTINEOPLASTIC AGENT; CHITOSAN NANOPARTICLE; DUAL POLYMER SMALL INTERFERING RNA; GLYCOL; POLYMER; PROTEIN BCL 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; BCL2 PROTEIN, HUMAN; CHITOSAN; GLYCOL-CHITOSAN; NANOPARTICLE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; GENE SILENCING; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RNA SEQUENCE; THERAPY EFFECT; TUMOR VOLUME; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; CHEMISTRY; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; NUDE MOUSE; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RNA INTERFERENCE; RNAI THERAPEUTICS; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CHITOSAN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MICE, NUDE; NANOPARTICLES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; TRANSFECTION; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84949529212     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.08.032     Document Type: Article

References (34)

1. J.C. Cheng, T.B. Moore, and K.M. Sakamoto RNA interference and human disease Mol. Genet. Metab. 80 2003 121 128
2. T.N. Campbell, and F.Y. Choy RNA interference: past, present and future Curr. Issues Mol. Biol. 7 2005 1 6
3. G.R. Devi siRNA-based approaches in cancer therapy Cancer Gene Ther. 13 2006 819 829
4. Y.K. Oh, and T.G. Park siRNA delivery systems for cancer treatment Adv. Drug Deliv. Rev. 61 2009 850 862
5. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
6. S. Zhang, B. Zhao, H. Jiang, B. Wang, and B. Ma Cationic lipids and polymers mediated vectors for delivery of siRNA J. Control. Release 123 2007 1 10
7. A.L. Bolcato-Bellemin, M.E. Bonnet, G. Creusat, P. Erbacher, and J.P. Behr Sticky overhangs enhance siRNA-mediated gene silencing Proc. Natl. Acad. Sci. U. S. A. 104 2007 16050 16055
8. X. Liu, C. Liu, E. Laurini, P. Posocco, S. Pricl, F. Qu, P. Rocchi, and L. Peng Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer Mol. Pharm. 9 2012 470 481
9. S.Y. Lee, M.S. Huh, S. Lee, S.J. Lee, H. Chung, J.H. Park, Y.K. Oh, K. Choi, K. Kim, and I.C. Kwon Stability and cellular uptake of polymerized siRNA (poly-siRNA)/polyethylenimine (PEI) complexes for efficient gene silencing J. Control. Release 141 2010 339 346
10. H. Yoo, and H. Mok Evaluation of multimeric siRNA conjugates for efficient protamine-based delivery into breast cancer cells Arch. Pharm. Res. 38 2014 129 136
11. J.B. Lee, J. Hong, D.K. Bonner, Z. Poon, and P.T. Hammond Self-assembled RNA interference microsponges for efficient siRNA delivery Nat. Mater. 11 2012 316 322
12. M.K. Joo, J.Y. Yhee, S.H. Kim, and K. Kim The potential and advances in RNAi therapy: chemical and structural modifications of siRNA molecules and use of biocompatible nanocarriers J. Control. Release 193 2014 113 121
13. S.J. Lee, J.Y. Yhee, S.H. Kim, I.C. Kwon, and K. Kim Biocompatible gelatin nanoparticles for tumor-targeted delivery of polymerized siRNA in tumor-bearing mice J. Control. Release 172 2013 358 366
14. J.Y. Yhee, S.J. Lee, S. Lee, S. Song, H.S. Min, S.W. Kang, S. Son, S.Y. Jeong, I.C. Kwon, S.H. Kim, and K. Kim Tumor-targeting transferrin nanoparticles for systemic polymerized siRNA delivery in tumor-bearing mice Bioconjug. Chem. 24 2013 1850 1860
15. J.H. Lee, and A. Nan Combination drug delivery approaches in metastatic breast cancer J. Drug Delivery 2012 2012 915375
16. S. Son, S. Song, S.J. Lee, S. Min, S.A. Kim, J.Y. Yhee, M.S. Huh, I. Chan Kwon, S.Y. Jeong, Y. Byun, S.H. Kim, and K. Kim Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors Biomaterials 34 2013 9475 9485
17. S.J. Lee, M.S. Huh, S.Y. Lee, S. Min, S. Lee, H. Koo, J.U. Chu, K.E. Lee, H. Jeon, Y. Choi, K. Choi, Y. Byun, S.Y. Jeong, K. Park, K. Kim, and I.C. Kwon Tumor-homing poly-siRNA/glycol chitosan self-cross-linked nanoparticles for systemic siRNA delivery in cancer treatment Angew. Chem. 51 2012 7203 7207
18. W. Tai, B. Qin, and K. Cheng Inhibition of breast cancer cell growth and invasiveness by dual silencing of HER-2 and VEGF Mol. Pharm. 7 2010 543 556
19. M.A. Shibata, J. Morimoto, E. Shibata, and Y. Otsuki Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model Cancer Gene Ther. 15 2008 776 786
20. L. Han, A.L. Zhang, P. Xu, X. Yue, Y. Yang, G.X. Wang, Z.F. Jia, P.Y. Pu, and C.S. Kang Combination gene therapy with PTEN and EGFR siRNA suppresses U251 malignant glioma cell growth in vitro and in vivo Med. Oncol. 27 2010 843 852
21. D. Grimm, and M.A. Kay Combinatorial RNAi: a winning strategy for the race against evolving targets? Mol. Ther. 15 2007 878 888
22. S. Sonoke, T. Ueda, K. Fujiwara, Y. Sato, K. Takagaki, K. Hirabayashi, T. Ohgi, and J. Yano Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes Cancer Res. 68 2008 8843 8851
23. Y. Takei, K. Kadomatsu, Y. Yuzawa, S. Matsuo, and T. Muramatsu A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics Cancer Res. 64 2004 3365 3370
24. I. Arnaoutova, and H.K. Kleinman In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract Nat. Protoc. 5 2010 628 635
25. J.E. Nor, J. Christensen, D.J. Mooney, and P.J. Polverini Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression Am. J. Pathol. 154 1999 375 384
26. G. Perrone, B. Vincenzi, D. Santini, A. Verzi, G. Tonini, A. Vetrani, and C. Rabitti Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer Cancer Lett. 208 2004 227 234
27. J.Y. Yhee, S. Song, S.J. Lee, S.G. Park, K.S. Kim, M.G. Kim, S. Son, H. Koo, I.C. Kwon, J.H. Jeong, S.Y. Jeong, S.H. Kim, and K. Kim Cancer-targeted MDR-1 siRNA delivery using self-cross-linked glycol chitosan nanoparticles to overcome drug resistance J. Control. Release 198 2015 1 9
28. I. Arnaoutova, J. George, H.K. Kleinman, and G. Benton The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art Angiogenesis 12 2009 267 274
29. A.J. Raffo, H. Perlman, M.W. Chen, M.L. Day, J.S. Streitman, and R. Buttyan Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo Cancer Res. 55 1995 4438 4445
30. F. Ciardiello, and G. Tortora Inhibition of bcl-2 as cancer therapy Ann. Oncol. 13 2002 501 502
31. V. Kirkin, S. Joos, and M. Zornig The role of Bcl-2 family members in tumorigenesis Biochim. Biophys. Acta 1644 2004 229 249
32. X.X. Zhao, O.O. Ogunwobi, and C. Liu Survivin inhibition is critical for Bcl-2 inhibitor-induced apoptosis in hepatocellular carcinoma cells PLoS One 6 2011
33. E. Varin, C. Denoyelle, E. Brotin, M. Meryet-Figuiere, F. Giffard, E. Abeilard, D. Goux, P. Gauduchon, P. Icard, and L. Poulain Downregulation of Bcl-xL and Mcl-1 is sufficient to induce cell death in mesothelioma cells highly refractory to conventional chemotherapy Carcinogenesis 31 2010 984 993
34. J. George, N.L. Banik, and S.K. Ray Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth J. Cell. Mol. Med. 13 2009 4205 4218